| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abiraterone |
08.03.04.02 |
Restricted Use
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Adefovir Dipivoxil |
05.03.03 |
Restricted Use
|
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir Dipivoxil |
05.03.03 |
Restricted Use
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Aflibercept |
08.01 |
Formulary
|
NICE TA307 - Colorectal cancer (metastatic) - aflibercept: guidance |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA294: Macular degeneration (wet age-related) - aflibercept |
| Alirocumab |
02.12 |
Restricted Use
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Restricted Use
|
NICE TA177: Eczema (chronic) - alitretinoin |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Restricted Use
|
NICE TA156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275) |
| Apremilast |
08.02 |
Restricted Use
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast |
08.02 |
Restricted Use
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Aripiprazole |
04.02.01 |
Restricted Use
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213) |
| Aripiprazole |
04.02.01 |
Restricted Use
|
NICE TA292: Bipolar disorder (children) - aripiprazole (NICE TA292) |
| Aspirin (antiplatelet) |
02.09 |
Formulary
|
NICE CG107 - Hypertension in pregnancy |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Bempedoic acid |
02.12 |
Restricted Use
|
NICE TA 694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (April 2021) |
| Bempedoic acid with Ezetimibe |
02.12 |
Restricted Use
|
NICE TA 694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (April 2021) |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230: Bivalirudin for the treatment of STEMI, 2011 |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE CG94: Unstable angina and NSTEMI |
| Blinatumomab |
08.02.03 |
Restricted Use
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Boceprevir |
05.03.03 |
Formulary
|
NICE Guidance 2012 |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA129: Multiple myeloma - bortezomib |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA228:Bortezomib and thalidomide for the first-line treatment of multiple myeloma |
| Botulinum Toxin Type A |
04.07.04.02 |
Non Formulary
|
NICE TA260: Botox for migraine prophylaxis |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Budesonide |
01.05.02 |
Restricted Use
|
NICE TA 708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (June 2021) |
| Cabazitaxel |
08.01.05 |
Restricted Use
|
NICE TA255: Cabazitaxel for prostate cancer |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA60: Colorectal cancer - capecitabine and tegafur uracil |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA186: Rheumatoid arthritis - certolizumab pegol |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA145: Head and neck cancer - cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA176: Colorectal cancer (first line) - cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Colistimethate inhaler |
05.01.07 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA 597: Dapagliflozin with insulin for treating type 1 diabetes (Feb 2020) |
| Dapagliflozin |
02.05.05 |
Restricted Use
|
NICE TA 679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction (Feb 2021) |
| Dasatinib |
08.01.05 |
Restricted Use
|
NICE TA241: CML for whom treatment with imatinib has failed because of intolerance |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab: guidance |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women |
| Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema |
| Diltiazem 2% |
01.07.04 |
Restricted Use
|
NICE evidence summary |
| Docetaxel |
08.01.05 |
Formulary
|
NICE CG121: Lung Cancer - The diagnosis and treatment of lung cancer |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
| Domperidone |
04.06 |
Formulary
|
NICE: Promoting tolerance of enteral feeds in children and young people: domperidone |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) |
| Dronedarone |
02.03.02 |
Restricted Use
|
NICE TA197: Atrial fibrillation - dronedarone |
| Eltrombopag |
09.01.04 |
Restricted Use
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) |
| Empagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA336- Empagliflozin in combination therapy for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Restricted Use
|
NICE TA390- Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Entecavir |
05.03.03 |
Restricted Use
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir |
05.03.03 |
Restricted Use
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Eplerenone |
02.02.03 |
Restricted Use
|
NICE CG108: Chronic heart failure |
| Eribulin |
08.01.05 |
Restricted Use
|
NICE TA250: Breast cancer (advanced) - eribulin (TA250) |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA35: Arthritis (juvenile idiopathic) - etanercept |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA219: Everolimus for second-line treatment of renal cell cancer |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA294: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor): |
| Everolimus |
08.01.05 |
Restricted Use
|
NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Evolocumab |
02.12 |
Restricted Use
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exenatide |
06.01.02.03 |
Non Formulary
|
NICE TA248: MR exenatide |
| Ezetimibe |
02.12 |
Non Formulary
|
NICE TA132: Hypercholesterolaemia - ezetimibe |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Filgotinib |
10.01.03 |
Restricted Use
|
NICE TA 676: Filgotinib for treating moderate to severe rheumatoid arthritis (Feb 2021) |
| Finasteride |
06.04.02 |
Formulary
|
NICE CG97: Lower urinary tract symptoms: quick reference guide |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fluocinolone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA271: Diabetic macular oedema - fluocinolone acetonide intravitreal implant (TA271) |
| Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA25: Pancreatic cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gentamicin |
24.01 |
Restricted Use
|
NICE Guidance |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: Psoriatic arthritis - golimumab |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA233: Ankylosing spondylitis - golimumab |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA225: Rheumatoid arthritis - golimumab |
| Ibrutinib |
08.01.05 |
Restricted Use
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA70: Leukaemia (chronic myeloid) - imatinib |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant): guidance |
| Imatinib |
08.01.05 |
Restricted Use
|
NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Ipilimumab |
08.01.05 |
Non Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ivabradine |
02.06.03 |
Restricted Use
|
NICE Guidance on Stable Angina |
| Lapatinib |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE TA 664: Liraglutide for managing overweight and obesity (Dec 2020) |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE CG28: Type 2 diabetes in adults: management |
| Liraglutide |
04.05.01 |
Restricted Use
|
NICE TA 664: Liraglutide for managing overweight and obesity (Dec 2020) |
| Magnesium Glycerophosphate |
09.05.01.03 |
Formulary
|
NICE: Evidence Summary: Magnesium glycerophosphate |
| Mannitol inhalation |
03.07 |
Non Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation (TA266) |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE: Multiple Sclerosis; management in primary and secondary care. |
| MIDODRINE Tablets 2.5 mg, 5mg |
02.07.02 |
Formulary
|
NICE: Postural hypotension in adults: midodrine (ESUOM5) |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Modafinil |
04.04 |
Restricted Use
|
NICE: Evidence Summary (Apr 2013) |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Natalizumab |
08.02.04 |
Restricted Use
|
NICE TA127: Multiple sclerosis - natalizumab |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
| Nivolumab |
08.01 |
Restricted Use
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.01 |
Restricted Use
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.01 |
Restricted Use
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma (November 2016) |
| Obeticholic acid |
01.09.01 |
Restricted Use
|
NICE Ta 443: for primary biliary cholangitis |
| Ocriplasmin |
11.08.02 |
Restricted Use
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA201: Asthma (in children) - omalizumab |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA133: Asthma (uncontrolled) - omalizumab |
| Omega-3-Acid Ethyl Esters |
02.12 |
Formulary
|
NICE: schizophrenia - omega-3 fatty acid medicines |
| Omega-3-Marine Triglycerides |
02.12 |
Non Formulary
|
NICE: schizophrenia - omega-3 fatty acid medicines |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA55: Ovarian cancer - paclitaxel (review) |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA108: Breast cancer (early) - paclitaxel |
| Panitumumab |
08.01.05 |
Restricted Use
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Pazopanib |
08.01.05 |
Non Formulary
|
NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib |
| Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE guidance on pegaptanib in AMD (August 2008) |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab |
08.02.03 |
Restricted Use
|
NICE TA447 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.02.03 |
Restricted Use
|
NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.02.03 |
Restricted Use
|
NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.02.03 |
Restricted Use
|
NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124: Lung cancer (non-small-cell) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Perampanel |
04.08.01 |
Restricted Use
|
NICE evidence summary |
| Perampanel |
04.08.01 |
Restricted Use
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Perampanel |
04.08.01 |
Restricted Use
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pimecrolimus |
13.05.03 |
Restricted Use
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| pirfenidone |
17 |
Non Formulary
|
NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone (TA282) |
| Ponatinib |
08.01.05 |
Restricted Use
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel |
02.09 |
Restricted Use
|
NICE TA182: Acute coronary syndrome - prasugrel |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE quick reference guide on osteoporosis |
| Raltitrexed |
08.01.03 |
Formulary
|
NICE CG131 - Colorectal Cancer: The diagnosis and management of colorectal cancer |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance |
| Ranolazine |
02.06.03 |
Formulary
|
NICE Guidance on Stable Angina |
| Retigabine |
04.08.01 |
Restricted Use
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA110: Follicular lymphoma - rituximab Non-Hodgkins lymphoma - rituximab |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA137: Lymphoma (follicular non-Hodgkins) - rituximab |
| Rituximab |
08.02.03 |
Restricted Use
|
NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab |
| Rituximab (rheumatology) |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for AF |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for treatment of DVT |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism |
| Roflumilast |
03.03.03 |
Non Formulary
|
NICE Final Appraisal Determination Dec 2011 |
| Romiplostim |
09.01.04 |
Restricted Use
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Secukinumab |
10.01.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab |
10.01.03 |
Restricted Use
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Somatropin |
06.05.01 |
Non Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review) |
| Somatropin |
06.05.01 |
Non Formulary
|
NICE TA64: Growth hormone deficiency (adults) - human growth hormone |
| Sorafenib |
08.01.05 |
Non Formulary
|
NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Tacrolimus |
13.05.03 |
Restricted Use
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tadalafil |
07.04.05 |
Non Formulary
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273) |
| Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03 |
Non Formulary
|
NICE Guidance 2012 |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Brain cancer - temozolomide |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) |
| Temsirolimus |
08.01.05 |
Non Formulary
|
NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE CG165: Hepatitis B (chronic) - incorporates TA173 |
| Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Ticagrelor |
02.09 |
Restricted Use
|
NICE TA236 |
| Tinzaparin |
02.08.01 |
Formulary
|
NICE guideline [NG89] March 2018: Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism |
| Tobramycin inhaler |
05.01.04 |
Non Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276) |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA198: Rheumatoid arthritis - tocilizumab |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA91: Topotecan for ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Non Formulary
|
NICE TA222- ovarian cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vemurafenib |
08.01.05 |
Non Formulary
|
NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma |
| VibeX Rapid® |
11.08.02 |
Restricted Use
|
NICE IPG466- Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272) |
| Zolpidem |
04.01.01 |
Restricted Use
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Restricted Use
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
